Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron | B3 | Healthcare | Biotechnology & Medical Research | R$358.79B | 14.3x | 0.84 | R$56.69 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beigene | B3 | Healthcare | Biotechnology & Medical Research | R$160.97B | -61.7x | -1.42 | R$52.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings BDR | B3 | Healthcare | Biotechnology & Medical Research | R$135.61B | 18.7x | 68.02 | R$214.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | B3 | Healthcare | Biotechnology & Medical Research | R$135.53B | -27.4x | 0.03 | R$35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | B3 | Healthcare | Biotechnology & Medical Research | R$58.76B | -3.1x | -0.07 | R$7.56 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | B3 | Healthcare | Biotechnology & Medical Research | R$54.69B | -24.6x | -0.74 | R$59.46 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioTechne | B3 | Healthcare | Biotechnology & Medical Research | R$42.73B | 58.2x | -1.65 | R$9.18 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomm On | B3 | Healthcare | Biotechnology & Medical Research | R$1.31B | -17.4x | -0.54 | R$10.19 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |